Best Stock Screeners for Fundamental Investors in 2026: Seven Tools Compared

Which stock screener is best for fundamental investors in 2026? Stock Rover is a strong choice for sophisticated financial filters and historical comparisons; TIKR is particularly useful for global company research; Stock Analysis offers a low-cost route into financial data; and Finviz remains a practical free starting point for US stocks. Koyfin, Morningstar Investor, and TradingView serve distinct research needs. The best choice depends on whether you prioritize historical fundamentals, international coverage, analyst valuation work, or speed.

A stock screener narrows a large universe of companies using rules such as earnings growth, free cash flow, debt, and valuation. It does not determine whether a stock is worth buying. This comparison focuses on long-term fundamental investing, not day-trading alerts. Features and published US prices were checked against provider pages on November 10, 2026; subscriptions, promotions, and plan limits can change.

Quick Comparison: Seven Stock Screeners for 2026

Platform Best use for fundamental investors Free entry Published paid starting point
Stock Rover Deep criteria, historical and equation-based screening 14-day trial Premium $348/year, regular annual billing
TIKR Global financial history, estimates, and filings US stock tier Plus $24.95/month, monthly billing
Stock Analysis Affordable fundamental tables and screening Yes Pro $79/year
Koyfin Global research dashboards and peer comparisons Yes, with limits Plus $39/month, annual-plan rate
Finviz Fast US stock filtering Yes Elite $299.50/year
Morningstar Investor Analyst fair-value and moat research Trial Investor $249/year
TradingView Fundamentals combined with price charts Yes Paid tiers vary by plan and billing

How to read the price column: amounts are US-dollar prices published by providers, not like-for-like monthly commitments. A yearly plan may be cheaper per month than paying monthly; taxes, promotional discounts, data add-ons, and renewal prices can differ. This comparison uses published product documentation, not hands-on testing.

Which Stock Screener Should You Choose?

1. Stock Rover: Best for Advanced Fundamental Screening

Stock Rover targets investors who want to rank stocks using extensive financial criteria, compare ratios over time, and connect screening with portfolio analysis. Its Premium tier lists more than 300 screening metrics, while Premium Plus adds equation-based and historical screening, expanded data, and ranked screens. The regular annual Premium price displayed by the provider is $348; premium historical features require a higher tier.

Trade-off: the interface and advanced tiers demand more learning and spending than a basic screener. It is most defensible for investors who repeatedly research profitability, leverage, valuation, and the durability of financial performance, not those running one occasional screen.

2. TIKR: Best for Global Company Fundamentals

TIKR offers a free US-focused plan and paid international coverage. Its Plus plan lists access to more than 100,000 global stocks across 92 countries and 136 exchanges, with longer financial histories and more analyst estimates than the free tier. The provider lists Plus at $24.95 per month on monthly billing, with a lower effective rate for annual billing.

See also  How to Read a 10-K Annual Report Like an Analyst

Trade-off: the most extensive histories, premium metrics, and additional screening factors are reserved for higher plans. TIKR is compelling when the question is not merely “Which stocks have a low P/E?” but “Which companies across several markets have maintained growth and returns through different cycles?”

3. Stock Analysis: Best Budget Fundamental Screener

Stock Analysis has a straightforward screener with valuation, financial, dividend, and analyst views. The company advertises more than 300 filter choices in the current interface. Its Pro plan costs $79 a year and adds saved screens, longer financial histories, and more data-table options; the standard Pro plan limits exports to one download per day.

Trade-off: it is less suited to investors who need complex custom equations or a sophisticated historical ranking engine. For a reader building a consistent, inexpensive financial-analysis routine, its combination of free access and published annual pricing is attractive.

4. Koyfin: Best for Dashboards and Cross-Market Research

Koyfin combines stock screening with financial statements, estimates, market data, and configurable dashboards. Its free plan lists two saved screens and two years of financial data. Plus lists ten years of financial data and estimates, unlimited screens and watchlists, and broader global-company research at $39 per month on the displayed annual-plan rate.

Trade-off: the value comes from using the complete research workspace, not solely its filters. A US-only investor who wants a few basic ratios may not need that functionality. Investors who routinely compare sectors, countries, company forecasts, and market conditions may benefit more.

5. Finviz: Best Free Starting Point for US Stock Ideas

Finviz combines descriptive, fundamental, and technical screens in a fast interface. Its US stock coverage and familiar filters, including valuation multiples, profitability and earnings growth, make it useful for identifying a first shortlist. The free experience is sufficient for many simple screens. Finviz Elite, published at $299.50 annually or $39.50 monthly, adds capabilities such as advanced screening, exports, and real-time quotes.

Trade-off: Finviz is less focused on tracing a decade of accounting data or building bespoke historical fundamental equations. It is an idea generator rather than a substitute for studying the underlying Form 10-K and Form 10-Q.

6. Morningstar Investor: Best for Analyst-Led Valuation Context

Morningstar Investor complements numerical screening with analyst research, estimated fair values, and competitive-advantage assessments. Its published subscription price is $249 annually or $34.95 monthly. Investors who want an external view on business quality and valuation may find those tools more useful than a larger number of raw filters.

Trade-off: estimated fair value reflects assumptions and analyst judgments, not a guaranteed market outcome. Morningstar is better considered a second-stage research tool than a fully automated stock-selection answer.

See also  How to Analyze a Balance Sheet Before Buying a Stock

7. TradingView: Best for Fundamentals Alongside Charts

TradingView’s Stock Screener supports financial statement metrics, TTM and other period selections, multiples, revenue and earnings growth, ROIC, and leverage alongside technical indicators. It is useful when a fundamental investor also wants to inspect price, volume, and the timing of market reactions.

Trade-off: charting is not a substitute for reconciling financial statements. Saved screens, exports, update intervals, and market-data permissions vary by subscription. Start with the free version and review the relevant plan limits before paying.

What Makes a Screener Useful for Fundamental Investing?

Filter quality matters more than filter count. Look for transparent period definitions, consistent accounting treatment, and a way to confirm where each figure originated. Consider whether a tool distinguishes trailing twelve months (TTM) from the latest fiscal year, uses GAAP or adjusted earnings, updates after new filings, and treats negative denominators sensibly.

For an equity screen, the most informative categories generally include: revenue growth to assess demand; operating margin and return on invested capital (ROIC) to assess economics; cash from operations and free cash flow to assess funding; leverage and debt maturities to assess resilience; and P/E or enterprise-value multiples to assess price. For a precise distinction between equity and business-level multiples, see our P/E versus EV/EBITDA guide.

Historical consistency is especially important. A company may pass a single-year return threshold because of a temporary earnings gain, asset disposal, or unusually low invested-capital balance. Review multiple years and compare with peers before concluding that the business has a lasting advantage.

A Practical Fundamental Stock Screen: Worked Example

Suppose the goal is to identify established US nonfinancial companies for further research. The following thresholds are hypothetical teaching criteria, not recommended buy signals. Apply only the filters supported by your chosen screener:

  • Size: market capitalization of at least $2 billion, to exclude many smaller firms.
  • Growth: three-year revenue CAGR of at least 8%, calculated over comparable fiscal periods.
  • Profitability: positive operating income and ROIC above 12%, using one consistent ROIC definition.
  • Cash: positive annual free cash flow over each of the last three fiscal years.
  • Balance sheet: net debt/EBITDA below 2.0x where EBITDA is positive and the measure is appropriate.
  • Valuation: review forward P/E and EV/EBITDA against genuinely comparable peers rather than applying one universal maximum.

A screener may not expose three-year positive free cash flow as one rule. In that case, screen for current positive FCF, then inspect historical statements manually. Under a common simplified definition, free cash flow = cash from operations minus capital expenditures. Our free cash flow tutorial explains how capital investment can change the result.

See also  How to Analyze SaaS Companies Using ARR, RPO, and Free Cash Flow

For example, a hypothetical business with $600 million in annual free cash flow and a $12 billion equity market capitalization has an FCF yield of 5%: $600 million divided by $12,000 million equals 0.05. This is an equity-market-capitalization measure using the simplified FCF definition, not a forecast return. It can be misleading if cash flow is temporarily boosted by working capital or if leverage is substantial.

Why Screening Results Can Mislead Investors

Different sectors require different filters. Banks and insurers should not be ranked mechanically using industrial-company net debt/EBITDA or ordinary free cash flow. REITs require attention to funds from operations and property-level economics. Early-stage biotechnology businesses may be loss-making, making P/E and ROIC unusable. Always apply an industry-specific framework.

Vendor metrics are not audited filings. Providers can differ in their treatment of leases, acquisitions, one-time charges, preferred stock, and forecast earnings. Check the source date and the accounting definition. Use SEC EDGAR for the primary 10-K and 10-Q documents, and read the notes as well as the headline financial statements.

Low multiples are not necessarily bargains. A stock can appear cheap because its profits are cyclical or its business is deteriorating. Conversely, rapid sales growth does not automatically justify an expensive valuation. A Cloudflare-versus-Akamai comparison illustrates why investors must examine both growth and the price already paid for it.

Strong reported growth can hide important adjustments. Acquisition-driven growth, non-GAAP earnings, and stock-based compensation can alter an apparently attractive screen. Our Zeta Global earnings analysis shows why reported and underlying revenue growth, GAAP profit, and free cash flow should be reviewed separately. Check the company’s quarterly earnings red flags and balance-sheet quality before moving from a shortlist to a valuation.

Final Verdict: Start With the Workflow, Not the Subscription

For a free first screen, Finviz or Stock Analysis is a sensible starting point. Choose Stock Rover for advanced historical and equation-based filters, TIKR for global company financial histories, Koyfin for integrated market research, Morningstar Investor for analyst valuation context, or TradingView if chart-based confirmation is part of your process. Stock Analysis Pro is an especially accessible paid upgrade when financial data and simple screening matter more than complex modeling.

Run the same investment hypothesis across comparable data, identify which companies pass, and then independently check filings, accounting quality, competitive economics, balance-sheet risks, and valuation. A screener cannot eliminate risk or make arbitrary thresholds predictive.

Educational disclosure: This is general financial education, not personalized investment advice. Rankings are editorial assessments of documented capabilities, not a performance test or endorsement of future investment results. Prices and feature access were reviewed November 10, 2026.